Demographic and clinicopathologic characteristics of 54 subjects at diagnosis
| Characteristics . | n (%) . |
|---|---|
| Sex | |
| Female | 23 (43) |
| Male | 31 (57) |
| Age at enrollment | |
| <1 y | 15 (28) |
| 1–3 y | 39 (72) |
| Race | |
| Native American/Inuit | 1 (2) |
| Asian | 2 (4) |
| Black | 6 (11) |
| Mixed race | 4 (7) |
| White | 37 (69) |
| Other/unknown | 4 (7) |
| Tumor location | |
| Supratentorial | 12 (22) |
| Infratentorial (posterior fossa) | 42 (78) |
| Metastatic status | |
| M0 | 40 (74) |
| M1 | 1 (2) |
| MX | 13 (24) |
| Histology | |
| WHO grade II (classic) | 13 (24) |
| WHO grade III (anaplastic) | 41 (76) |
| Risk stratification | |
| Intermediate | 53 (98) |
| High | 1 (2) |
| Extent of resection at diagnosis | |
| Biopsy | 1 (2) |
| GTR | 29 (54) |
| NTR | 12 (22) |
| STR | 12 (22) |
| Characteristics . | n (%) . |
|---|---|
| Sex | |
| Female | 23 (43) |
| Male | 31 (57) |
| Age at enrollment | |
| <1 y | 15 (28) |
| 1–3 y | 39 (72) |
| Race | |
| Native American/Inuit | 1 (2) |
| Asian | 2 (4) |
| Black | 6 (11) |
| Mixed race | 4 (7) |
| White | 37 (69) |
| Other/unknown | 4 (7) |
| Tumor location | |
| Supratentorial | 12 (22) |
| Infratentorial (posterior fossa) | 42 (78) |
| Metastatic status | |
| M0 | 40 (74) |
| M1 | 1 (2) |
| MX | 13 (24) |
| Histology | |
| WHO grade II (classic) | 13 (24) |
| WHO grade III (anaplastic) | 41 (76) |
| Risk stratification | |
| Intermediate | 53 (98) |
| High | 1 (2) |
| Extent of resection at diagnosis | |
| Biopsy | 1 (2) |
| GTR | 29 (54) |
| NTR | 12 (22) |
| STR | 12 (22) |
M1, metastatic disease—ie, CSF dissemination; MX, metastatic state unknown (ie, CSF not obtained).
Demographic and clinicopathologic characteristics of 54 subjects at diagnosis
| Characteristics . | n (%) . |
|---|---|
| Sex | |
| Female | 23 (43) |
| Male | 31 (57) |
| Age at enrollment | |
| <1 y | 15 (28) |
| 1–3 y | 39 (72) |
| Race | |
| Native American/Inuit | 1 (2) |
| Asian | 2 (4) |
| Black | 6 (11) |
| Mixed race | 4 (7) |
| White | 37 (69) |
| Other/unknown | 4 (7) |
| Tumor location | |
| Supratentorial | 12 (22) |
| Infratentorial (posterior fossa) | 42 (78) |
| Metastatic status | |
| M0 | 40 (74) |
| M1 | 1 (2) |
| MX | 13 (24) |
| Histology | |
| WHO grade II (classic) | 13 (24) |
| WHO grade III (anaplastic) | 41 (76) |
| Risk stratification | |
| Intermediate | 53 (98) |
| High | 1 (2) |
| Extent of resection at diagnosis | |
| Biopsy | 1 (2) |
| GTR | 29 (54) |
| NTR | 12 (22) |
| STR | 12 (22) |
| Characteristics . | n (%) . |
|---|---|
| Sex | |
| Female | 23 (43) |
| Male | 31 (57) |
| Age at enrollment | |
| <1 y | 15 (28) |
| 1–3 y | 39 (72) |
| Race | |
| Native American/Inuit | 1 (2) |
| Asian | 2 (4) |
| Black | 6 (11) |
| Mixed race | 4 (7) |
| White | 37 (69) |
| Other/unknown | 4 (7) |
| Tumor location | |
| Supratentorial | 12 (22) |
| Infratentorial (posterior fossa) | 42 (78) |
| Metastatic status | |
| M0 | 40 (74) |
| M1 | 1 (2) |
| MX | 13 (24) |
| Histology | |
| WHO grade II (classic) | 13 (24) |
| WHO grade III (anaplastic) | 41 (76) |
| Risk stratification | |
| Intermediate | 53 (98) |
| High | 1 (2) |
| Extent of resection at diagnosis | |
| Biopsy | 1 (2) |
| GTR | 29 (54) |
| NTR | 12 (22) |
| STR | 12 (22) |
M1, metastatic disease—ie, CSF dissemination; MX, metastatic state unknown (ie, CSF not obtained).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
